Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis
This article was originally published in The Pink Sheet Daily
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
You may also be interested in...
TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications
Medco/Mayo study links more precise warfarin dosing through genotyping to a 30 percent reduction in hospitalization rates compared with patients not tested prior to starting therapy.
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.